metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Estudio de los alelos HLA-C en el bocio multinodular
Journal Information
Vol. 74. Issue 6.
Pages 334-339 (December 2003)
Share
Share
Download PDF
More article options
Vol. 74. Issue 6.
Pages 334-339 (December 2003)
Full text access
Estudio de los alelos HLA-C en el bocio multinodular
Visits
6061
Antonio Ríosa,1
Corresponding author
ARZRIOS@teleline.es

Correspondencia: Dr. A. Ríos. Avda. de la Libertad, 208. 30007 Casillas. Murcia. España.
, José Manuel Rodrígueza, María Rosa Moyab, Pedro José Galindoaa, Manuel Canterasc, María Rocío Álvarezb, Pascual Parrillaa
a Servicio de Cirugía General y del Aparato Digestivo I. Hospital Universitario Virgen de la Arrixaca. Murcia.
b Servicio de Inmunología. Hospital Universitario Virgen de la Arrixaca. Murcia.
c Departamento de Bioestadística. Hospital Universitario Virgen de la Arrixaca. Murcia. España.
This item has received
Article information
Resumen
Introducción

Clásicamente, el bocio multinodular ha sido considerado una enfermedad tiroidea no autoinmune. Sin embargo, en la actualidad su origen sigue siendo incierto y existen varias alteraciones inmunológicas que no permiten descartarlo. El objetivo es determinar si existe alguna asociación entre el bocio multinodular y los alelos HLA-C.

Pacientes y método

Se realiza la tipificación de los genes HLA-C mediante la técnica de biología molecular PCR-SSP en 90 bocios multinodulares intervenidos quirúrgicamente. Como grupo control se utilizó una muestra de 100 controles caucasianos sanos no relacionados representativos de la población. Las variables analizadas son la edad, el sexo, los antecedentes familiares de enfermedad tiroidea, la clínica del paciente, la gradación clínica del bocio, el componente intratorácico tiroideo, el peso del tiroides y el carcinoma asociado. Para el análisis estadístico se han utilizado el test de la ?2 y la corrección de Bonferroni.

Resultados

Se observa una menor frecuencia del alelo HLA-Cw4 en el bocio multinodular (15,5 frente a 8,3%; p = 0,0012), con un riesgo relativo de 0,49 (0,9- 0,26). Al analizar las distintas variables clínicas, la asociación más importante es la ausencia del alelo Cw4 con la presencia de bocios con componente intratorácico (p = 0,0012) y con la presencia de bocios de más de 200 g (p = 0,0233).También se observa una asociación entre la presencia del alelo Cw7 y los antecedentes familiares de enfermedad tiroidea, y entre la presencia de un carcinoma asociado y el alelo Cw1.

Conclusiones

El HLA-Cw4 se comporta como un alelo protector contra el desarrollo del bocio multinodular, pues no sólo aparece con menor frecuencia en la población con esta enfermedad sino que las personas que presentan este alelo desarrollan bocios más pequeños y sin componente intratorácico.

Palabras clave:
Bocio multinodular
HLA
Etiopatogenia
HLA-Cw4
HLA-Cw1
HLA-Cw7
Introduction

Classically, multinodular goiter (MG) has been considered a nonimmune thyroid disease. However, currently its etiology remains uncertain and several immunological alterations indicate that an autoimmune etiology cannot be ruled out. The aim of the present study was to determine whether there is an association between MG and HLA-C alleles.

Patients and method

typing for hla-c using the molecular biology technique of sequence specific primers (pcr-ssp) was performed in 90 patients with mg who underwent surgery. the control group was composed of 100 healthy, unrelated caucasians, representative of the population. the variables analyzed were age, sex, family history of thyroid disease, symptomatology, clinical degree of the goiter, intrathoracic thyroid component, thyroid weight, and associated carcinoma. statistical analysis was performed using the chi-square test and bonferroni’s correction.

Results

the frequency of the hla-cw4 allele was lower in mg (15.5% versus 8.3%; p = 0.0012), with a relative risk of 0.49 (0.9-0.26). analysis of the clinical variables revealed that the most important association was the absence of cw4 allele with the presence of goiters with intrathoracic components (p = 0.0012) and with the presence of goiters of more than 200 g (p = 0.0233). an association was also observed between the presence of the cw7 allele and familial antecedents of thyroid disease and between the presence of associated carcinoma and the cw1 allele.

Conclusions

hla-cw4 behaves as a protective allele against the development of mg not only because it is less frequent in the population with mg but also because individuals presenting this allele develop smaller goiters without an intrathoracic component.

Key words:
Multinodular goiter
HLA
Etiopathogenesis
HLA-Cw4
HLA-Cw1
HLA-Cw7
Full text is only aviable in PDF
Bibliografía
[1.]
D.L. Hurley, H. Gharib.
Evaluation and management of multinodular goiter.
Otolaryngol Clin North Am, 29 (1996), pp. 527-540
[2.]
J. Aguayo, Y. Sakatsume, C. Jamieson, V.V. Row, R. Volpe.
Non toxic nodular goiter and papillary thyroid carcinoma are not associated with peripheral blood lymphocyte sensitization to thyroid cells.
J Clin Endocrinol Metab, 68 (1989), pp. 145-149
[3.]
R. Jansson, A. Karlsson, V. Forsum.
Intrathyroidal HLA-DR expression and T lymphocyte phenotypes in Graves’ thyrotoxicosis, Hashimoto’s thyroiditis and nodular colloid goiter.
Clin Exp Immunol, 58 (1984), pp. 264-272
[4.]
R.D. Van der Gaag, H.A. Drexhage, W.M. Wiersinga, R.S. Brown, R. Docter, G.F. Bottazzo, et al.
Further studies on thyroid growth stimulating immunoglobulins in euthyroid nonendemic goiter.
J Clin Endocrinol Metab, 60 (1985), pp. 972-979
[5.]
P.J. Kabel, H.A.M. Voorbij, M. De Haan, R.D. Van der Gaag, H.A. Drexhage.
Intrathyroidal dendritic dells.
J Clin Endocrinol, 66 (1988), pp. 199-207
[6.]
Z. Kraiem, B. Glaser, M. Yigla, J. Pauker, O. Sadeh, M. Sheinfeld.
Toxic multinodular goiter: a variant of autoimmune hyperthyroidism.
J Clin Endocrinol Metab, 65 (1987), pp. 659-664
[7.]
J.J. Corrales, A. Orfao, J.M. Miralles, M.C. López Berges, L.C. García, M. González, et al.
Immunological features of sporadic multinodular goiter.
Clin Invest, 71 (1993), pp. 552-558
[8.]
B. Grubeck, K. Derfler, H. Kassal, W. Knapp, K. Krisch, K. Liszka, P.PA. Smyth, et al.
Immunological features of non immunogenic hyperthyroidism.
J Clin Endocrinol Metab, 60 (1985), pp. 150-155
[9.]
J.R. Wall, R. Baur, H. Schleusener, P. Bandy.
Peripheral blood and intrathyroidal mononuclear cell populations in patients with autoimmune thyroid disorders enumerated using monoclonal antibodies.
J Clin Endocrinol Metab, 56 (1983), pp. 164-169
[10.]
D. Rigopoulou, Laso J Martínez, F. Martínez Tello, J.F. Alcaide, D. Benmamar, F. Hawkins, et al.
Both class I and class II HLA antigens are thyroid cancer susceptibility factors.
Tissue Antigens, 43 (1994), pp. 281-285
[11.]
S. Ahuja, I. Hoppe, H. Von Keyserlingk, H. Ernst.
HLA and thyroid carcinoma.
Exp Clin Endocrinol, 99 (1992), pp. 134-136
[12.]
M. Bunce, K.I. Welsh.
Rapid DNA typing for HLA-C using sequence specific primers (PCR-SSP): identification of serological and nonserologically defined HLA-C alleles including several new alleles.
Tissue Antigens, 43 (1994), pp. 7-17
[13.]
M. Bunce, M.C.N.M. Barnardo, K.I. Welsh.
Improvements in HLA-C typing using sequence specific primers (PCR-SSP) including definition of HLA-Cw9 and Cw10 and a new allele HLA-“Cw7/8v”.
Tissue Antigens, 44 (1994), pp. 200-203
[14.]
J.E. Levine, S.Y. Yang.
SSOP typing of the Tenth International Histocompatibility Workshop reference cell lines for HLA-C alleles.
Tissue Antigens, 44 (1994), pp. 174-183
[15.]
H. Ando, N. Mizuki, R. Ando, Y. Miyata, S. Miyata, K. Wakisaka, et al.
HLA-C genotyping in the japanese population by the PCR-SSP method.
Tissue Antigens, 48 (1996), pp. 55-58
[16.]
M. Dahan, J. Gaillard, H. Eschapase.
Surgical treatment of goiters with intrathoracic development..
Thoracic surgery: frontiers and uncommon neoplasms. International trends in general thoracic surgery., pp. 5
[17.]
L.P. Svejgaard.
HLA and disease associations: detecting the strongest association.
Tissue Antigens, 43 (1994), pp. 18
[18.]
G.W. Geelhoed.
Tracheomalacia from compressing goiter: management after thyroidectomy.
Surgery, 104 (1988), pp. 1100-1108
[19.]
N. Takahata.
MHC diversity and selection.
Immunol Rev, 143 (1995), pp. 225-247
[20.]
L.J. DeGroot, J. Quintans.
The causes of autoimmune thyroid disease.
Endocr Rev, 10 (1989), pp. 537-562
[21.]
R.J. Duquesnoy.
Immunogenetics of the human major histocompatibility complex.
Clin Lab Med, 11 (1991), pp. 509-536
[22.]
J. Heward, S.C. Gough.
Genetic susceptibility to the development of autoimmune disease.
Clin Sci (Colch, 93 (1997), pp. 479-491
[23.]
A.P. Weetman.
New aspects of thyroid immunity.
Horm Res, 48 (1997), pp. 51-54
[24.]
E. Thorsby.
Invited anniversary review: HLA associated disease.
Human Immunology, 53 (1997), pp. 1-11
[25.]
S.M. McLachlan.
The genetic basis of autoimmune thyroid disease: time to focus on chromosomal loci other than the Major Histocompatibility Complex (HLA in man.
J Clin Endocrinol Metab, 77 (1993),
[26.]
T.A. Dalton, J.C. Bennett.
Autoimmune disease and the major histocompatibility complex: therapeutic implications.
Am J Med, 92 (1992), pp. 183-188
[27.]
K. Kotsa, F. Watson, A.P. Weetman.
A CTLA-4 gene polymorphism is associated with both Graves’ disease and autoimmune hypothyroidism.
Clin Endocrinol (Oxf, 46 (1997), pp. 551-554
[28.]
N.R. Farid.
Are the immune responses to endocrine autoantigens genetically restricted?.
Autoimmunity, 3 (1989), pp. 47-55
[29.]
H. Tamai, A. Kimura, R.P. Dong, S. Matsubayashi, K. Kuma Nagataki, T. Sasazuki.
Resistance to autoimmune thyroid disease is associated with HLA-DQ.
J Clin Endocrinol Metab, 78 (1994), pp. 94-97
[30.]
T. Yanagawa, A. Mangklabruks, L.J. DeGroot.
Strong association between HLA-DQA1*0501 and Graves’ disease in a male caucasian population.
J Clin Endocrinol Metab, 79 (1994), pp. 227-229
[31.]
B.Y. Cho, J.H. Chung, Y.K. Shong, Y.B. Chang, H. Han, J.B. Lee, et al.
A strong association between thyrothopin receptor blocking antibody positive atrophic autoimmune thyroiditis and HLA-DR8 and HLADQB1* 0320 in koreans.
J Clin Endocrinol Metab, 77 (1993), pp. 611-615
[32.]
K. Honda, H. Tamai, T. Morita, K. Kuma, Y. Nishimura, T. Sasazuki.
Hashimoto’s thyroiditis and HLA in japanese.
J Clin Endocrinol Metab, 69 (1989), pp. 1268-1273
[33.]
J. Maenpaa, I. Lautenschlager, M. Nyberg, S. Koskimies, S. Kontiaimen.
Thyroid infiltrating lymphocytes, thyroid function, and HLA-DR in juvenile autoimmune thyroiditis.
Acta Endocrinol (Copenh, 121 (1989), pp. 573-577
[34.]
A.B. Parkes, C. Darke, S. Othman, M. Thomas, N. Young, C.J. Richards, et al.
Major histocompatibility complex class II and complement polymorphisms in postpartum thyroiditis.
Eur J Endocrinol, 134 (1996), pp. 449-453
[35.]
U. Bogner, K. Badenhoop, H. Peters, P.D. Schmieg, W.R. Mayr, K.H. Usadel.
HLA-DR/DQ gene variation in nongoitrous sutoimmune thyroiditis at the serological and molecular level.
Autoimmunity, 14 (1992), pp. 155-158
[36.]
B.L. Rosawskii, M.N. Dimovaa, T.P. Kiseleva, L.G. Akhmed’ianova, V.M. Minina.
Antigens of the HLA system in nodular formations of the thyroid gland (artículo en ruso) [abstract].
Probl Endokrinol (Mosk, 39 (1993), pp. 28-30
[37.]
C. Papasteriades, M.N. Alevizaki, J. Economidou, D.G. Ikkos.
HLA antigens in Greek patients with thyrotoxicosis (Graves’ disease and toxic nodular goiter.
J Endocrinol Invest, 7 (1984), pp. 283-286
[38.]
O. Ozaki, K. Ito, K. Kobayashi, A. Suzuku, Y. Manabe, Y. Hosoda.
Familial occurrence of differentiated, nonmedullary thyroid carcinoma.
World J Surg, 12 (1988), pp. 565-571
[39.]
S. Koyama, Y. Mitsuishi, K. Bibee, I. Watanabe, P.I. Terasaki.
HLA associations with Meniere’s disease.
Acta Otolaryngol, 113 (1993), pp. 575-578
[40.]
P. Ivanyi, D. Ivanyi, P. Zemek.
HLA Cw4 in paranoid schizophrenia.
Tissue Antigens, 9 (1977), pp. 41-44
[41.]
S. Wakitani, K. Imoto, T. Mazuka, S. Kim, N. Murata, M. Yoneda.
Japanese generalised osteoarthritis was associated with HLA class I a study of HLA-A, B, Cw, DR in 72 patients.
Clin Rheumatol, 20 (2001), pp. 417-419
[42.]
M.M. Bortin, J. D’Amaro, F.H. Bach, A.A. Rimm, J.J. van Rood.
HLA associations with leukemia.
Blood, 70 (1987), pp. 227-232
[43.]
C. Grundschober, M.P. Labonne, F. Javaux, Q.G. Steiner, L. Gebuhrer, J.M. Tiercy.
Sequence of four new HLA-Cw alleles: a possible role of interallelic recombination.
Tissue Antigens, 51 (1998), pp. 72-79
[44.]
L. Sanz, F. González Escribano, R. de Pablo, A. Nuñez Roldan, M. Kreisler, C. Vilches.
HLA-Cw*1602: a new susceptibility marker of Behçet’s disease in southern Spain.
Tissue Antigens, 51 (1998), pp. 111-114
[45.]
H. Hendel, S. Caillat Zucman, H. Lebuanec, M. Carrington, S. O’Brien, J.M. Adrieu, et al.
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.
J Immunol, 162 (1999), pp. 6942-6946
[46.]
S. Carrel, M. Schreyer, G. Spagnoli, J.C. Cerottini, D. Rimoldi.
Monoclonal antibodies against recombinant MAGE 1 protein identify a cross reacting 72 kDa antigen which is co-expressed with MAGE 1 protein in melanoma cells.
[47.]
P. Van der Bruggen, J.P. Szikora, P. Boel, C. Wildmann, M. Somville, M. Sensi, et al.
Autologous cytolytic T lymphocytes recognize a MAGE 1 nonapeptide on melanomas expressing HLA-Cw*1601.
Eur J Immunol, 24 (1994), pp. 2134-2140
[48.]
K. Araki, Y. Noguchi, T. Hirouchi, E. Yoshikawa, S. Kataoka, L. Silverni, et al.
Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in japanese patients with advanced cancer.
Int J Oncol, 617 (2000), pp. 1107-1118
[49.]
L. Heidecker, F. Brasseur, M. Probst-Kepper, M. Gueguen, T. Boon, B.J. Van den Eynde.
Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGEA12.
J Immunol, 164 (2000), pp. 6041-6045
[50.]
A. Ríos, J.M. Rodríguez, J. Illana, N.M. Torregrosa, P. Parrilla.
Familial papillary carcinoma of the thyroid. Report of 3 families.
Eur J Surg, 167 (2001), pp. 339-343
[51.]
G. From, A. Mellemgaard, N. Knudsen, T. Jorgensen, H. Perrild.
Review of thyroid cancer cases among patients with previous benign thyroid disorders.
Thyroid, 10 (2000), pp. 697-700
Copyright © 2003. Asociación Española de Cirujanos
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos